Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED

Conditions

• Dry Eye Syndromes
• Dry Eye Disease (DED)

Interventions

• DEVICE: FBV_01
• DEVICE: HYLO-VISION® SafeDrop® Gel

Sponsor

FB Vision S.p.A